| scholarly article | Q13442814 |
| P2093 | author name string | Daniel M Musher | |
| Nancy Logan | |||
| Herbert L Dupont | |||
| Arnold Lentnek | |||
| Arvind Gupta | |||
| Richard J Hamill | |||
| Jean-Francois Rossignol | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Clostridium difficile | Q310543 |
| Clostridioides difficile colitis | Q574905 | ||
| P304 | page(s) | 421-427 | |
| P577 | publication date | 2006-07-11 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Nitazoxanide for the treatment of Clostridium difficile colitis | |
| P478 | volume | 43 |
| Q30240264 | A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection |
| Q36904890 | Acute infectious pediatric gastroenteritis: beyond oral rehydration therapy |
| Q37813126 | Alternative therapies for Clostridium difficile infections |
| Q37992487 | An overview of the diagnosis and management of Clostridium difficile infection |
| Q24234378 | Antibiotic treatment for Clostridium difficile -associated diarrhea in adults |
| Q24244302 | Antibiotic treatment for Clostridium difficile-associated diarrhea in adults |
| Q30235446 | Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults |
| Q36942502 | Antibiotics and resistance genes: influencing the microbial ecosystem in the gut. |
| Q30442308 | Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni |
| Q44085925 | Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis |
| Q40721471 | Australasian Society of Infectious Diseases updated guidelines for the management of Clostridium difficile infection in adults and children in Australia and New Zealand |
| Q24644191 | Bench-to-bedside review: Clostridium difficile colitis |
| Q35611260 | Binaphthyl-1,2,3-triazole peptidomimetics with activity against Clostridium difficile and other pathogenic bacteria. |
| Q33793074 | Challenges of antibacterial discovery |
| Q43297981 | Changing Clostridium difficile infection testing and treatment trends at a large tertiary care teaching hospital |
| Q37633859 | Clinical update for the diagnosis and treatment of Clostridium difficile infection |
| Q38445227 | Clostridium Difficile Infection from a Surgical Perspective. |
| Q27016320 | Clostridium difficile Infection in Children: Current State and Unanswered Questions |
| Q37160538 | Clostridium difficile associated infection, diarrhea and colitis |
| Q33276804 | Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide |
| Q34260389 | Clostridium difficile colitis: a review |
| Q93600959 | Clostridium difficile infection in patients with inflammatory bowel disease |
| Q47142602 | Clostridium difficile infection in the elderly: an update on management |
| Q34234668 | Clostridium difficile infection in the inflammatory bowel disease patient. |
| Q37305032 | Clostridium difficile infection in the intensive care unit |
| Q37662628 | Clostridium difficile infection in the intensive care unit |
| Q37176641 | Clostridium difficile infection: a critical overview |
| Q37970002 | Clostridium difficile infection: clinical spectrum and approach to management |
| Q35372397 | Clostridium difficile infection: current, forgotten and emerging treatment options |
| Q37216863 | Clostridium difficile infection: emerging concepts and treatments |
| Q36523440 | Clostridium difficile infection: new insights into management |
| Q24632641 | Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance |
| Q36870734 | Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. |
| Q37287190 | Clostridium difficile-associated disease in human stem cell transplant recipients: coming epidemic or false alarm? |
| Q36757577 | Clostridium difficile-associated disease: changing epidemiology and implications for management |
| Q36861661 | Clostridium difficile: recent epidemiologic findings and advances in therapy |
| Q36961050 | Community-Acquired Clostridium Difficile Infection: Awareness and Clinical Implications |
| Q59882555 | Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis |
| Q46586095 | Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin |
| Q38538221 | Controversies Around Epidemiology, Diagnosis and Treatment of Clostridium difficile Infection |
| Q41832378 | Current Treatment Options for Severe Clostridium difficile-associated Disease |
| Q38023283 | Current state of Clostridium difficile treatment options |
| Q38248112 | Diagnosis and management of common gastrointestinal tract infectious diseases in ulcerative colitis and Crohn's disease patients |
| Q46040308 | Effects of nitazoxanide on pharmacokinetics and pharmacodynamics of a single dose of warfarin. |
| Q26786662 | Efficacy and Safety of Metronidazole Monotherapy versus Vancomycin Monotherapy or Combination Therapy in Patients with Clostridium difficile Infection: A Systematic Review and Meta-Analysis |
| Q35164536 | Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections |
| Q36984883 | Emerging therapies for Clostridium difficile infection - focus on fidaxomicin |
| Q37858531 | Emerging therapies for Clostridium difficile infections |
| Q36659957 | Emerging therapies in the treatment of Clostridium difficile-associated disease |
| Q87624349 | Enteric infections |
| Q38068605 | Epidemiology, diagnosis and treatment of Clostridium difficile infection |
| Q36647979 | Fecal transplant in refractory Clostridium difficile colitis |
| Q94400472 | Fecal transplantation for recurrent or refractory Clostridium difficile diarrhea |
| Q24234630 | Fecal transplantation for recurrent or refractory Clostridium difficile diarrhea |
| Q37743525 | Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection |
| Q37910246 | Fidaxomicin: first-in-class macrocyclic antibiotic |
| Q35175136 | Future novel therapeutic agents for Clostridium difficile infection |
| Q35912682 | In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004 |
| Q38787320 | Management of Clostridium difficile Infection |
| Q47577721 | Measurement of selected preventable adverse drug events in electronic health records: Toward developing a complexity score |
| Q37052819 | New advances in the treatment of Clostridium difficile infection (CDI) |
| Q37779102 | New antibiotics for selective treatment of gastrointestinal infection caused by Clostridium difficile |
| Q34602195 | New antimicrobial agents for patients with Clostridium difficile infections |
| Q37537353 | New antimicrobial agents for the treatment of bacterial infections in cancer patients |
| Q30433333 | Newer antibacterial drugs for a new century |
| Q80688787 | Nitazoxanide in the treatment of amoebiasis |
| Q28483646 | Nitazoxanide stimulates autophagy and inhibits mTORC1 signaling and intracellular proliferation of Mycobacterium tuberculosis |
| Q33398747 | Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study |
| Q27021914 | Nitazoxanide: a first-in-class broad-spectrum antiviral agent |
| Q28242385 | Nitazoxanide: a review of its use in the treatment of gastrointestinal infections |
| Q40149924 | Nitazoxanide: clinical studies of a broad-spectrum anti-infective agent |
| Q37678601 | Nitazoxanide: nematicidal mode of action and drug combination studies |
| Q55405974 | Novel Antimicrobials for the Treatment of Clostridium difficile Infection. |
| Q38032858 | Novel management strategies in the treatment of severe Clostridium difficile infection. |
| Q91611858 | Novel therapies and preventative strategies for primary and recurrent Clostridium difficile infections |
| Q40438125 | Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. |
| Q36674768 | Past, present, and future therapies for Clostridium difficile-associated disease |
| Q99207599 | Quantitative proteomic analysis of the tizoxanide effect in vero cells |
| Q27022537 | Recent changes in Clostridium difficile infection |
| Q38547127 | Recently disclosed chemical entities as potential candidates for management of tuberculosis |
| Q89814511 | Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postope |
| Q35822541 | Recurrent Clostridium difficile infection: From colonization to cure |
| Q37419829 | Recurrent Clostridium difficile infection: causality and therapeutic approaches |
| Q37875055 | Recurrent Clostridium difficile infection: what are the treatment options? |
| Q39554726 | Successful use of nitazoxanide in the treatment of recurrent Clostridium difficile infection. |
| Q42180828 | Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea |
| Q30229530 | The challenges posed by reemerging Clostridium difficile infection |
| Q36889259 | The ecology and pathobiology of Clostridium difficile infections: an interdisciplinary challenge |
| Q37111226 | The management of Clostridium difficile infection: antibiotics, probiotics and other strategies |
| Q28082059 | The potential for emerging therapeutic options for Clostridium difficile infection |
| Q38757930 | Therapies on the horizon for Clostridium difficile infections |
| Q38139991 | Therapy of Clostridium difficile infection: perspectives on a changing paradigm |
| Q37481436 | Thiazolides: a new class of antiviral drugs |
| Q37277077 | Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C. |
| Q35155775 | Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives |
| Q36270659 | Treatment of Clostridium difficile infection in mice with vancomycin alone is as effective as treatment with vancomycin and metronidazole in combination |
| Q51894323 | Treatment of Clostridium difficile infection. |
| Q34710368 | Treatment of Clostridium difficile infection: recent trial results |
| Q37602531 | Treatment of recurrent Clostridium difficile infection: a systematic review. |
| Q37346005 | Treatment strategies for recurrent and refractory Clostridium difficile-associated diarrhea |
| Q39638001 | Type IV pili promote early biofilm formation by Clostridium difficile |
| Q93002732 | Updates in Treatment of Recurrent Clostridium difficile Infection |
Search more.